Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Questcor Pharmaceuticals
So what: The company reported record sales of $31.3 million and net income of $11.5 million, or $0.18 per share. Acthar drove performance this quarter, as its use in multiple sclerosis patients increased.
Now what: Sales nearly tripled from last year as the company put itself on more solid financial footing. The performance of Acthar is encouraging, and with Food and Drug Administration approval to market Acthar to treat infantile spasms, I see this stock continuing today's run. I'm buying the growth story and can't get in the way of a growth stock on a roll.
Interested in more info on Questcor Pharmaceuticals? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.